Novel data point to a broader mechanism of action of oxidized ATP: The P2X 7 receptor is not the only target

British Journal of Pharmacology

Volumn 140, Issue 3, 2003, Pages 441-443

  Di Virgilio, Francesco ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Danger signals; Extracellular ATP; Inflammation; P2X 7 receptor; Schiff base

Indexed keywords

ADENOSINE TRIPHOSPHATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; OXIDIZED ADENOSINE TRIPHOSPHATE; PURINE P2X RECEPTOR; PURINE P2X7 RECEPTOR; SCHIFF BASE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CYTOKINE RELEASE; DRUG ACTIVITY; DRUG RECEPTOR BINDING; EXTRACELLULAR SPACE; GENE ACTIVATION; IMMUNOMODULATION; MONONUCLEAR PHAGOCYTE; OXIDATION; PRIORITY JOURNAL; PROTEIN TARGETING; RECEPTOR BLOCKING; REVIEW;

ADENOSINE TRIPHOSPHATE; ANIMALS; HUMANS; OXIDATION-REDUCTION; RECEPTORS, PURINERGIC P2;

EID: 0142216130     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705469     Document Type: Review

References (14)

1. BEIGI, R., KERTESY, S., AQUILINA, G. & DUBYAK, G. (2003). Oxidized ATP (oATP) attenuates proinflammatory signaling via P2 receptor-independent mechanisms. Br. J. Pharmacol., 140, 507-519.
2. BURNSTOCK, G. (1996). A unifying purinergic hypothesis for the initiation of pain. Lancet, 347, 1604-1605.
3. CHARO, J., SUNDBACK, M., WASSERMAN, K., CIUPITU, A-M.T., MIRZAI, B., VAN DER ZEE, R. & KIESSLING, R. (2002). Marked enhancement of the antigen-specific immune response by combining plasmid DNA-based immunization with a Schiff base-forming drug. Infect. Immun., 70, 6652-6657.
4. DI VIRGILIO, F., CHIOZZI, P., FERRARI, D., FALZONI, S., SANZ, J.M., MORELLI, A., TORBOLI, M., BOLOGNESI, G. & BARICORDI, O.R. (2001). Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood, 97, 587-600.
5. GALLUCCI, F. & MATZINGER, P. (2001). Danger signals: SOS to the immune system. Curr. Opin. Immunol., 13, 114-119.
6. 7 nucleotide receptor reveals its regulatory roles in bone formation and resorption. Mol. Endocrinol., 17, 1356-1367.
7. 7 receptor in immune cells of the brain and periphery. J. Biol. Chem., 276, 23262-23267.
8. 7 receptor alters leukocyte function and attenuates an inflammatory response. J. Immunol, 168, 6436-6445.
9. LAMBRECHT, G., FRIEBE, T., GRIMM, U., WINDSCHEIF, U., BUNGARDT, E., HILDEBRANDT, C., BAUMERT, H.G., SPATZ-KUMBEL, G. & MUTSCHLER, E. (1992). PPADS, a novel functionally selective antagonist of P2 purinoceptor-mediated responses. Eur. J. Pharmacol., 217, 217-219.
10. LA SALA, A., FERRARI, D., DI VIRGILIO, F., IDZKO, M., NORGAUER, J. & GIROLOMONI, G. (2003). Alerting and tuning the immune response by extracellular nucleotides. J. Leukoc. Biol., 73, 339-343.
11. 2Z receptor. J. Biol. Chem., 268, 8199-8203.
12. RHODES, J. (2002). Discovery of immunopotentiatory drugs: current and future strategies. Clin. Exp. Immunol., 130, 363-369.
13. RHODES, J., CHEN, H., HALL, S.R., BEESLEY, J.E., JENKINS, D.C., COLLINS, P. & ZHENG, B. (1995). Therapeutic potentiation of the immune system by costimulatory Schiff-base-forming drugs. Nature, 377, 71-75.
14. 7). Science, 212, 735-738.